Shandong Shanda Wit Science and Technology Co Ltd (000915) - Total Liabilities
Based on the latest financial reports, Shandong Shanda Wit Science and Technology Co Ltd (000915) has total liabilities worth CN¥573.21 Million CNY (≈ $83.88 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shandong Shanda Wit Science and Technology Co Ltd - Total Liabilities Trend (1996–2024)
This chart illustrates how Shandong Shanda Wit Science and Technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 000915 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Shandong Shanda Wit Science and Technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Shanda Wit Science and Technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ADLINK Technology Inc
TW:6166
|
Taiwan | NT$7.22 Billion |
|
Aebi Schmidt Holding AG - Common Stock
NASDAQ:AEBI
|
USA | $1.48 Billion |
|
Imperial Metals Corporation
TO:III
|
Canada | CA$878.77 Million |
|
Haesung DS Co Ltd
KO:195870
|
Korea | ₩327.52 Billion |
|
Beijing Kingee Culture Development Co Ltd
SHE:002721
|
China | CN¥244.97 Million |
|
Piraeus Port Authority S.A
AT:PPA
|
Greece | €226.60 Million |
|
Ameresco Inc
NYSE:AMRC
|
USA | $3.33 Billion |
|
First Hi-tec Enterprise Co Ltd
TWO:5439
|
Taiwan | NT$7.77 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Shandong Shanda Wit Science and Technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shandong Shanda Wit Science and Technolo stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Shanda Wit Science and Technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Shanda Wit Science and Technology Co Ltd (1996–2024)
The table below shows the annual total liabilities of Shandong Shanda Wit Science and Technology Co Ltd from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥518.50 Million ≈ $75.87 Million |
-26.10% |
| 2023-12-31 | CN¥701.65 Million ≈ $102.67 Million |
+11.55% |
| 2022-12-31 | CN¥629.03 Million ≈ $92.05 Million |
+17.35% |
| 2021-12-31 | CN¥536.03 Million ≈ $78.44 Million |
-29.44% |
| 2020-12-31 | CN¥759.72 Million ≈ $111.17 Million |
+29.80% |
| 2019-12-31 | CN¥585.32 Million ≈ $85.65 Million |
+4.72% |
| 2018-12-31 | CN¥558.92 Million ≈ $81.79 Million |
+0.46% |
| 2017-12-31 | CN¥556.37 Million ≈ $81.41 Million |
+4.40% |
| 2016-12-31 | CN¥532.89 Million ≈ $77.98 Million |
+32.78% |
| 2015-12-31 | CN¥401.35 Million ≈ $58.73 Million |
-15.04% |
| 2014-12-31 | CN¥472.42 Million ≈ $69.13 Million |
+9.45% |
| 2013-12-31 | CN¥431.63 Million ≈ $63.16 Million |
+9.04% |
| 2012-12-31 | CN¥395.83 Million ≈ $57.92 Million |
+1.41% |
| 2011-12-31 | CN¥390.33 Million ≈ $57.12 Million |
-20.16% |
| 2010-12-31 | CN¥488.86 Million ≈ $71.54 Million |
-16.15% |
| 2009-12-31 | CN¥582.99 Million ≈ $85.31 Million |
-2.32% |
| 2008-12-31 | CN¥596.85 Million ≈ $87.34 Million |
-0.48% |
| 2007-12-31 | CN¥599.73 Million ≈ $87.76 Million |
+5.09% |
| 2006-12-31 | CN¥570.70 Million ≈ $83.51 Million |
-6.24% |
| 2005-12-31 | CN¥608.70 Million ≈ $89.07 Million |
+36.78% |
| 2004-12-31 | CN¥445.01 Million ≈ $65.12 Million |
+7.12% |
| 2003-12-31 | CN¥415.43 Million ≈ $60.79 Million |
+34.86% |
| 2002-12-31 | CN¥308.04 Million ≈ $45.08 Million |
+29.02% |
| 2001-12-31 | CN¥238.76 Million ≈ $34.94 Million |
+69.51% |
| 2000-12-31 | CN¥140.86 Million ≈ $20.61 Million |
+31.26% |
| 1999-12-31 | CN¥107.31 Million ≈ $15.70 Million |
-7.75% |
| 1998-12-31 | CN¥116.33 Million ≈ $17.02 Million |
-1.98% |
| 1997-12-31 | CN¥118.68 Million ≈ $17.37 Million |
+2.51% |
| 1996-12-31 | CN¥115.78 Million ≈ $16.94 Million |
-- |
About Shandong Shanda Wit Science and Technology Co Ltd
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration s… Read more